SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are facing significant volatility as investors weigh strong quarterly earnings and record backlog growth against the company's aggressive $40 billion financing plan to fund AI infrastructure. While the community remains divided over the long-term ROI of massive capital expenditures, many are actively debating whether the current sell-off is a rational response to balance sheet concerns or a broader market reaction to the ongoing AI infrastructure spending cycle.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Nasdaq is under significant selling pressure as investors liquidate mega-cap tech holdings to raise liquidity for the highly anticipated SpaceX IPO and respond to mounting macro concerns. Market participants are actively debating the sustainability of AI valuations and reacting to geopolitical tensions in the Middle East, while many traders rotate into cash or defensive sectors to prepare for potential near-term volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amidst investor scrutiny over shifting corporate merger plans and broader market volatility driven by regional geopolitical tensions and rising inflation. The community remains deeply polarized, with active debates surfacing over the company's long-term valuation and the administration's ongoing foreign policy and economic impact.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is facing significant investor backlash as a massive capital raise fuels concerns over share dilution and management credibility. While some investors remain optimistic about the company's long-term backlog and AI infrastructure role, the community is deeply divided, with many citing past scandals and perceived mismanagement as reasons to stay on the sidelines.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is experiencing high volatility as investors react to the R2 SUV launch, which has triggered a "sell the news" trend and intense debate over its leasing pricing and overall demand. While some community members remain bullish on the long-term potential of the R2 platform and new software revenue streams, others are expressing frustration with the stock's inability to maintain gains amid a broader market correction.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending as investors grapple with significant volatility driven by shifting geopolitical tensions in the Middle East and cooling safe-haven demand. The community is actively debating whether current price action represents a temporary consolidation or a more structural breakdown, with heavy focus on technical support levels and the impact of looming economic data on the precious metals sector.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trading amidst high volatility as the community remains deeply divided over the legitimacy of purported peace negotiations between the U.S. and Iran. Investors are currently weighing intense geopolitical tensions and supply chain disruptions against persistent market skepticism regarding official announcements of an imminent deal.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing significant downward pressure as investors rotate capital out of established tech holdings to secure liquidity for the highly anticipated SpaceX IPO. While analysts continue to highlight the company's progress in autonomous driving technology, the community remains polarized between those viewing current share price levels as a deep-value buying opportunity and those concerned about the broader impact of Musks interconnected corporate ecosystem.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is trending as the market reacts to a new distribution agreement with NBCUniversal that restores access to key channels, a milestone seen by some investors as a catalyst to boost subscriber growth and competitive positioning. While bulls are highlighting the deal as a sign of potential stabilization and long-term upside, the community remains deeply divided, with many expressing skepticism due to previous dilution concerns and ongoing debates over the stock's future trajectory.

Cartesian Growth Corp III is a blank-check company that is sponsored by Cartesian Capital Group LLC. The company aims to acquire or merge with an established, high-growth business seeking access to public markets and capital. The company provides financial and operational expertise post-combination.

Factorial Energy Inc. - Ordinary Shares- Class A

Factorial Energy is trending as traders speculate on a potential short squeeze fueled by its low public float and high-profile partnerships with major automotive players. The community is actively debating the stock's massive volatility and the long-term viability of its solid-state battery technology compared to market incumbents.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment

LIXTE Biotechnology Holdings (NASDAQ: LIXT)&#160;is advancing the precision oncology landscape, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. “The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects,” reads a recent article. [&#8230;]

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape

Boca Raton, Florida-based&#160;LIXTE Biotechnology Holdings (NASDAQ: LIXT)&#160;spent 2025 expanding its presence across multiple segments of oncology innovation. “The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (‘PP2A’),” a recent article reads. “Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. [&#8230;]

LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference

LIXTE Biotechnology Holdings (NASDAQ: LIXT),&#160;a clinical-stage pharmaceutical company advancing cancer treatments, announced preliminary results from a clinical trial evaluating its proprietary compound LB-100 in combination with&#160;dostarlimab&#160;at the 2026 Society of Gynecologic Oncology conference in San Juan, Puerto Rico. Interim data from 20 evaluable patients showed a 40% disease control rate and encouraging survival trends with [&#8230;]

Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

Lixte Biotechnology (NASDAQ: LIXT)&#160;is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness of existing. As a clinical-stage pharmaceutical company, the company is advancing novel compounds built around a unique biological target, with its lead candidate, LB-100, at the nucleus of its [&#8230;]

LIXTE Biotechnology (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100. The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing&#8230; [&#8230;]

LIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need for new approaches. LIXTE Biotechnology Holdings (NASDAQ: LIXT) is dedicated to addressing that need through the continued development of its lead compound LB-100. Recent updates from the company highlight expanding clinical [&#8230;]

Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

Lixte Biotech Holdings (NASDAQ: LIXT)&#160;is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects. By focusing on [&#8230;]

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Boca Raton, FL.

LIXTLixte Biotechnology Holdings Inc

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest LIXT News